Pathophysiology and clinical features of Wilson disease

被引:97
作者
Ferenci, P [1 ]
机构
[1] Med Univ Vienna, Dept Internal Med 4, A-1090 Vienna, Austria
关键词
Wilson disease; copper metabolism; genetics; treatment;
D O I
10.1023/B:MEBR.0000043973.10494.85
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Wilson disease is an autosomal recessive inherited disorder of copper metabolism resulting in pathological accumulation of copper in many organs and tissues. ATP7B is the gene product of the Wilson disease gene located on chromosome 13 and resides in hepatocytes in the trans-Golgi network, transporting copper into the secretory pathway for incorporation into apoceruloplasmin and excretion into the bile. Mutations of the gene result in impaired trafficking of copper in and through the hepatocytes. More than 200 mutations of Wilson disease gene were found, the most common ones being H1069Q (in Europe) and R778L (in Asia). Wilson disease may present under a variety of clinical conditions, commonly as liver and/or neuropsychiatric disease. The pathogenesis of hepatic and neurologic Wilson disease is a direct consequence of copper accumulation. Presence of copper causes oxidative stress resulting in cell destruction. The diagnosis of Wilson disease requires a combination of a variety of clinical symptoms, biochemical tests, and detection of gene mutations, which are the basis of a score proposed by a group of international experts. Initial treatment for symptomatic patients should include a chelating agent (penicillamine or trientine). Treatment of presymptomatic patients or maintenance therapy can also be accomplished with zinc.
引用
收藏
页码:229 / 239
页数:11
相关论文
共 63 条
  • [1] [Anonymous], 2001, METABOLIC MOL BASES
  • [2] Structure of the Alzheimer's disease amyloid precursor protein copper binding domain - A regulator of neuronal copper homeostasis
    Barnham, KJ
    McKinstry, WJ
    Multhaup, G
    Galatis, D
    Morton, CJ
    Curtain, CC
    Williamson, NA
    White, AR
    Hinds, MG
    Norton, RS
    Beyreuther, K
    Masters, CL
    Parker, MW
    Cappai, R
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (19) : 17401 - 17407
  • [3] Cerebral manifestation of Wilson's disease successfully treated with liver transplantation
    Bax, RT
    Hassler, A
    Luck, W
    Hefter, H
    Krageloh-Mann, I
    Neuhaus, P
    Emmrich, P
    [J]. NEUROLOGY, 1998, 51 (03) : 863 - 865
  • [4] CLINICAL-DIFFERENTIATION OF FULMINANT WILSONIAN HEPATITIS FROM OTHER CAUSES OF HEPATIC-FAILURE
    BERMAN, DH
    LEVENTHAL, RI
    GAVALER, JS
    CADOFF, EM
    VANTHIEL, DH
    [J]. GASTROENTEROLOGY, 1991, 100 (04) : 1129 - 1134
  • [5] Borjigin J, 1999, J NEUROSCI, V19, P1018
  • [6] Treatment of Wilson disease with ammonium tetrathiomolybdate .2. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy
    Brewer, GJ
    Johnson, V
    Dick, RD
    Kluin, KJ
    Fink, JK
    Brunberg, JA
    [J]. ARCHIVES OF NEUROLOGY, 1996, 53 (10) : 1017 - 1025
  • [7] THE WILSON DISEASE GENE IS A PUTATIVE COPPER TRANSPORTING P-TYPE ATPASE SIMILAR TO THE MENKES GENE
    BULL, PC
    THOMAS, GR
    ROMMENS, JM
    FORBES, JR
    COX, DW
    [J]. NATURE GENETICS, 1993, 5 (04) : 327 - 337
  • [8] High prevalence of the H1069Q mutation in East German patients with Wilson disease:: rapid detection of mutations by limited sequencing and phenotype-genotype analysis
    Caca, K
    Ferenci, P
    Kühn, HJ
    Polli, C
    Willgerodt, H
    Kunath, B
    Hermann, W
    Mössner, J
    Berr, F
    [J]. JOURNAL OF HEPATOLOGY, 2001, 35 (05) : 575 - 581
  • [9] Screening for Wilson's disease in patients with liver diseases by serum ceruloplasmin
    Cauza, E
    MaierDobersberger, T
    Polli, C
    Kaserer, K
    Kramer, L
    Ferenci, P
    [J]. JOURNAL OF HEPATOLOGY, 1997, 27 (02) : 358 - 362
  • [10] Compston A, 1912, Brain, V34, P1997, DOI [10.1093/brain/awp193, DOI 10.1093/BRAIN/AWP193, DOI 10.1093/BRAIN/34.4.295]